Get started
MERCK & CO INCMERCK & CO INCMERCK & CO INC

MERCK & CO INC

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Bonds

MRK trade ideas

$MRK - that fake out!!This is a perfect example of the manipulation that can occur in the market. They intentionally sold this down below the trend line and massive consolidation since beginning of 2020. It was done right before a massive announcement. It shows the importance of being invested in quality, buying at the right price, and holding through until you find fundamental reasons not to. Trading is dangerous because the technicians and algos know how to mess you up. GLL!!!
NYSE:MRK
by UnknownUnicorn16739272
MERCK GOOD OPPORTUNITY Merck & Co., Inc., d.b.a. Merck Sharp & Dohme outside the United States and Canada, is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668. Merck & Co. was established as an American affiliate in 1891 Entry on the bullish break of the dynamic trendine or on exceeding the weekly maximum. Excellent operation with a risk / return ratio of 1.20
NYSE:MRKLong
by UnknownUnicorn25541012
MRK Testing the upper limits But Can It Make New Highs?MRK is back in this 382-236 fib range with both lining up pretty tightly with the current levels on the chart. 382 is a bit looser and more of a pivot area, for now, that's been a magnet for the stock over the last few weeks. Meanwhile, 236 was tested a few times and MRK was rejected each time. With the last update on Keytruda, it's going to be interesting to see what comes next. "Merck’s (NYSE:MRK) big news on July 27th marked a watershed moment for the company’s cancer treatment, Keytruda. The Food & Drug Administration approved Keytruda for treating patients with high-risk early-stage triple-negative breast cancer (TNBC), in combination with chemotherapy. Following surgery, Keytruda could then continue as a single agent adjuvant. This approval was based on Merck’s Phase 3 KEYNOTE-522 trial....Merck’s (NYSE: MRK) blockbuster drug, Keytruda, and Bristol-Myers’ YERVOY treatments target the same checkpoint inhibitors that are part of the B7 family (PD-1/PD-L1 and CTLA-4/CD80). They’ve also both demonstrated a clear survival benefit when it comes to immune-oncology treatment...This B7H3 protein is a checkpoint molecule, which has very recently become a target for cancer treatment." Quote Source & Read More: Hot Biotech Stocks To Watch After Sanofi’s Acquisition Of Translate Bio
NYSE:MRK
by PennyStocks101
MRK GREAT FUNDAMENTAL LONG ,We have a bounce with strenght on the MA 2000, prce looking to fell up the previous GAP. Price moving due to earnings, we looking for a big raise in next months. Price target between $100- $102 ( SV LeeRink / Truist Securities / JP Morgan) BIG funds Buying this stock, : - Warren Buffett - Berkshire Hathaway Add 28.10% -Mark Hillman - Hillman Fund Add 54.95% -Lee Ainslie - Maverick Capital Add 161.78% Important note: ⚠️ All trades have risks that the investor must consider before investing. VivirdelTrading.club makes a disclaimer of any operation that may generate losses. All information transmitted by the channel, the page and the alert system is shared in good faith. There is no guarantee of 100% of the executed operations, as these are based on statistical models and assumptions regarding the past behavior of the price of a share, but they do not guarantee the same future behavior.
NYSE:MRKLong
by Vivir_Del_Trading
Traditional|MRK|LongLong MRK Activation of the transaction only when the blue zone is fixed/broken. The author recommends the use of anchoring fixed the blue zone, this variation is less risky. If there is increased volatility in the market and the price is held for more than 2-3 minutes behind the activation zone after the breakdown, then the activation of the idea occurs at the prices behind the activation zone. The idea is to work out the resistance level . * Possible closing of a trade before reaching the take/stop zone. The author can close the deal for subjective reasons, this does not completely cancel the idea and is not a call to the same action, you can continue working out the idea according to your data, but without the support of the author. + Maybe right now we will go even lower, then it's okay, the idea is not activated and simply canceled. + ! - zone highlighted by the ellipse is a zone of increased resistance, in this area there is a possible reversal for a correction, please take this factor into account in this transaction. The "forecast" tool is used for more noticeable display of % (for the place of the usual % scale) of the price change, I do not put the date and time of the transaction, only %. Blue zones - activation zones, 2 activation zones are indicated ( A1-at the exit from the support zone and A2-at the support). Green zones - take zones. Red zone - stop zone, 2 stop zones are indicated (A1- "L-SL1", A2-"L-SL2"). Working out the stop when the price returns to the level after activation + fixing in the red zone. Orange arrow - the direction of take. The red arrow - the direction of the stop. SUM PNL: This parameter displays the total % of all closed ideas of the "new" format (according to the author) for this sector at the time of publication of the idea. The calculation is very "clumsy" just the sum of the profits of all the ideas, based on this indicator, you can more accurately assess the risks when working with my ideas of this sector. I present you the construction of the idea, you can use it yourself as you like based on your subjective view and risks, the calculation of the PNL indicator is carried out only on transactions that the author closed on TV in manual mode or by take. P.S Please use RM (risk management) and MM (money management) if you decide to use my ideas, there will always be unprofitable ideas, this will definitely happen, the goal of the system is that there will be more profitable ideas at a distance.
NYSE:MRKLong
by Henry_Ross
12
MRK investing ideaHi everyone, here will be Merck and Company. This company produce pharmaceutical products from many diseases (including cancer, cardiometabolic and so on). Most of sales (40%) are in USA. So, why i think, that this company is fine to long-term investing? Reasons: + Dividend payments 3,3% + Payback ratio 2,1% + Good results of work (net margine - 14,7%) + Return on Invested Capital is better then WACC, that shows business eficiency + sharp growning of Research and Development cost comparing to the 2019. + Administrative costs become lesser with a growth of revenues + Accounts receivable become lesser too + Growth of producing equipment (buying other companies), company expect rising of saling products on markets And now value of MRK is undervalued, so i think, at period of statements publication that will be strong growth in price, that will be good chance too. It will be usefull for long and short-term investment too.
NYSE:MRKLong
by ValueInvest_Pro